search

Active clinical trials for "Nasopharyngeal Neoplasms"

Results 1-10 of 208

Nivolumab in Children and Adults With Nasopharyngeal Carcinoma

Nasopharyngeal CarcinomaNasopharyngeal Cancer2 more

The purpose of this study is to assess whether the addition of the immune checkpoint inhibitor Nivolumab to induction chemotherapy will increase the percentage of patients with a complete response on MRI and PET after 3 cycles of induction therapy.

Recruiting38 enrollment criteria

Combining RT With Toripalimab and Chemotherapy in Metastatic Nasopharyngeal Carcinoma

Metastatic Nasopharyngeal Cancer

Incidences of de novo metastatic nasopharyngeal carcinoma range from 6% to 8% at the time of presentation. For the initial diagnosis of metastatic NPC, PD-1 plus chemotherapy yields a satisfactory outcome with1year PFS of 40%. Previous study demonstrated the benefit of adding radiotherapy to chemotherapy in metastatic NPC, however there is no evidence whether radiotherapy can further improve PFS based on chemotherapy plus PD-1 . The purpose of this study is to evaluate the safety and effectiveness of first-line immunochemotherapy combined with radiotherapy for initial diagnosed metastatic NPC.

Recruiting19 enrollment criteria

PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal...

Nasopharyngeal Neoplasms

This trial is aimed to investigate whether adjuvant PD-1 antibody treatment could improve survival in locoregionally advanced nasopharyngeal carcinoma compared to best supportive care.

Recruiting23 enrollment criteria

Sirolimus for Cowden Syndrome With Colon Polyposis

PTEN Gene MutationPTEN Hamartoma Tumor Syndrome5 more

Colon polyposis (the presence of multiple colon polyps) is very common with Cowden syndrome, as over 60% of patients have 50 or more polyps. In a previous clinical trial, some participants had reduction in the number of colon polyps with the use of the medication sirolimus for a very short time period. This study is investigating sirolimus and its effect on the number of colon polyps in patients with Cowden syndrome and polyposis over a 1 year period.

Recruiting10 enrollment criteria

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic...

Pancreatic CancerHepatocellular Cancer9 more

This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors. The aims of the study are: to assess the safety profile of TAK-500 when given alone and when given with pembrolizumab. to assess the effects of TAK-500, when given alone and when given with pembrolizumab, on adults with locally advanced or metastatic solid tumors. Participants may receive TAK-500 for up to 1 year. Participants may continue with their treatment if they have continuing benefit and if this is approved by their study doctor. Participants who are receiving TAK-500 either alone or with pembrolizumab will continue with their treatment until their disease progresses or until they or their study doctor decide they should stop this treatment.

Recruiting34 enrollment criteria

Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr...

Nasopharyngeal CancerEpstein-Barr Virus Related Carcinoma

To evaluate the anti cancer effect of VK 2019 in subjects with EBV related nasopharyngeal carcinoma (NPC) for whom there is no other standard treatment available

Recruiting32 enrollment criteria

Oligo-metastases NPC Patients Received Radiation for Primary Tumors and Treatments for Metastatic...

Nasopharyngeal CancerNeoplasm Metastasis

Oligo-metastases NPC patients received radiation for primary tumors and treatments for metastatic lesions.

Recruiting13 enrollment criteria

EpCAM CAR-T for Treatment of Advanced Solid Tumors

Malignant Neoplasm of Nasopharynx TNM Staging Distant Metastasis (M)Breast Cancer Recurrent1 more

This study is for patients that have nasopharyngeal carcinoma, breast cancer, gastric cancer and other solid tumors. As epithelial cell adhesion molecule (EpCAM) is a well characterized molecule that is closely with poor prognosis and tumor metastasis and invasion. Many therapies targeting EpCAM have shown benefits for cancer patients. This study is to determine the safety of the engineered T cells armed with chimeric antigen receptor (CAR-T) recognizing EpCAM. At the same time, efficacy is to be evaluated by the criteria of RECIST. The EpCAM CAR-T were produced by lentiviral transduction of the novel 2nd generation of CAR genes. Different cohorts of patients receive EpCAM CAR-T with a dose-escalating manner. This study is to find the largest dose of EpCAM CAR-T, to learn what the adverse effects are and to find out whether this experimental intervention might help patients with nasopharyngeal carcinoma, breast cancer and other EpCAM positive solid tumors.

Recruiting25 enrollment criteria

Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in

Metastatic Nasopharyngeal Cancer

This study is the first phase II study of 177Lu-DOTA0-Tyr3-Octreotate in metastatic NPC. Patients whom have failed 2 or more lines of therapy or exhausted standard therapy and are avid on 68Ga-DOTATATE imaging will be eligible to receive up to 4 cycles of 177Lu-DOTA0-Tyr3-Octreotate. The primary outcome will be progression free survival at 6 months.

Recruiting32 enrollment criteria

To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic...

Recurrent / Metastatic Nasopharyngeal Cancer

This study is a single-arm, randomized, open-label, multi-cohort Phase Ib clinical trial. The experimental drug is TQB2858 Injection. The trial was divided into 3 cohorts. Cohort 1 included patients with advanced nasopharyngeal carcinoma who had previously failed platinum-based chemotherapy and immune checkpoint inhibitors (programmed cell death protein 1 (PD-1)/ Programmed death-ligand 1 (PD-L1), etc.). Cohorts 2 and 3 were randomized into patients with advanced, untreated nasopharyngeal carcinoma who had not received prior systemic therapy. A total of 60-90 subjects are required.

Recruiting55 enrollment criteria
12...21

Need Help? Contact our team!


We'll reach out to this number within 24 hrs